摘要
目的观察肠愈宁治疗活动期溃疡性结肠炎大肠湿热证患者的临床疗效。方法选择符合纳入标准的溃疡性结肠炎大肠湿热证的患者40例,予以肠愈宁治疗,疗程为4周。观察指标为治疗前、后的中医症状、体征及结肠镜下黏膜病理变化,血清C反应蛋白及免疫球蛋白G变化情况,并对其结果进行统计学分析。结果肠愈宁治疗溃疡性结肠炎大肠湿热证的临床总有效率、中医证候总有效率及结肠镜下肠黏膜病变的总有效率分别是86.49%、89.19%、83.78%。治疗后,中医证候总积分显著降低,血清CRP、IgG水平明显降低,且差异有统计学意义(P<0.05)。结论肠愈宁治疗溃疡性结肠炎大肠湿热证患者的临床疗效显著。
Objective To observe the clinical efficacy of Changyuning in the treatment of active ulcerative colitis(UC) with colorectal dampness-heat syndrome.Methods Forty patients with UC with colorectal dampness-heat syndrome who met the inclusion criteria were enrolled and treated with Changyuning for 4 weeks.The changes in clinical efficacy,signs and symptoms of traditional Chinese medicine(TCM),histopathological changes under colonoscopy,and the levels of serum C-reactive protein(CRP) and immunoglobulin G(IgG) of patients before and after treatment were observed and analyzed.Results The clinical total effective rate of Changyuning in the treatment of UC with colorectal dampness-heat syndrome was 86.49%,the total effective rate of TCM syndrome and intestinal mucosal lesions under colonoscopy was 89.19% and 83.78%,respectively.After treatment,the total score of TCM syndrome and the serum levels of CRP and IgG were decreased significantly(P<0.05).Conclusion The effect of Changyuning is remarkable in the treatment of patients with UC with colorectal dampness-heat syndrome.
引文
[1] 张玉洁,梁洁,吴开春.炎症性肠病诊断与治疗的共识意见(2018 年,北京)溃疡性结肠炎部分解读[J].中华消化杂志,2018,38(5):312-314.
[2] 周凤,吴静.溃疡性结肠炎内科治疗的进展[J].世界华人消化杂志,2016,24(20):3149-3158.
[3] 谢晶日,孙涛,张冰.溃疡性结肠炎的中医药治疗进展及相关优势探讨[J].辽宁中医杂志,2016,43(2):425-427.
[4] 王常松.从西医治疗溃疡性结肠炎的难点看中医治疗优势[J].陕西中医学院学报,2008,31(4):3-5.
[5] 陈灏珠,钟南山,陆再英,等.内科学[M].北京:人民卫生出版社,2013:385-390.
[6] 中华医学会消化病学分会炎症性肠病学组.我国炎症性肠病诊断与治疗的共识意见[J].内科理论与实践,2013,8(1):61-75.
[7] 中国中西医结合学会消化系统疾病专业委员会.溃疡性结肠炎中西医结合诊疗指南(草案)[J].中国中西医结合消化杂志,2011,19(1):61-65.
[8] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:129-134.
[9] 陈治水,王新月.溃疡性结肠炎中西医结合诊疗共识[J].现代消化及介入治疗,2011,16(1):66-70.
[10] 马铭泽,杨崇美.多药耐药基因与溃疡性结肠炎的研究进展[J].世界华人消化杂志,2009,17(34):3530-3533.
[11] 黄彪,谢璐霜,吴巧凤.溃疡性结肠炎的中西医治疗进展及思考[J].实用医学杂志,2018,34(13):2267-2269,2274.
[12] 郭家英,韩真.免疫抑制剂联合生物制剂在炎症性肠病治疗中的新进展[J].沈阳医学院学报,2018,20(5):455-459,474.
[13] 张春艳,张晋嫄.中医治疗溃疡性结肠炎[J].长春中医药大学学报,2014,30(1):74-76.
[14] 林静.肠愈宁颗粒对溃疡性结肠炎大鼠JAK/STAT通路影响的研究[D].黑龙江中医药大学,2011.
[15] 蔡林宏.肠愈宁对溃疡性结肠炎大鼠S100、CD83、Foxp3及STAT6影响的研究[D].黑龙江中医药大学,2013.
[16] 王海强,郑丽红,朱峰,等.肠愈宁对溃疡性结肠炎大鼠炎性因子及钙卫蛋白释放的影响[J].世界中医药,2018,13(10):2547-2551.
[17] 王晓艳,邓文雯,李帅军,等.白芍七物颗粒口服联合药物保留灌肠治疗大肠湿热型溃疡性结肠炎的临床效果[J].中国医药,2017,12(11):1702-1705.
[18] 谢晶日,徐婷,李贺薇.肠愈宁颗粒治疗活动期溃疡性结肠炎临床观察[J].中华中医药学刊,2015,33(1):12-14.
[19] 孙志文,张杨,沈文娟.谢晶日教授治疗活动期溃疡性结肠炎经验撷英[J].浙江中医药大学学报,2017,41(4):295-297,314.
[20] 孙志文.清热化湿解毒法治疗溃疡性结肠炎大肠湿热证的临床观察[D].黑龙江中医药大学,2014.
[21] 龚信.古今医鉴[M].北京:中国中医药出版社,2007:113-114.
[22] 仝小林,何莉莎,赵林华.中医迈向精准时代的思考[J].中医杂志,2016,57(20):1715-1718.
[23] 墙登梅.血清C反应蛋白检测对评价溃疡性结肠炎病情的价值临床研究[J].临床和实验医学杂志,2012,11(3):193-194.
[24] 李琪佳,徐敏,张雪怡,等.免疫复合物IgG及补体C3c在溃疡性结肠炎免疫发病机制中的作用[J].中国综合临床,2001,17(8):614-615.